Five Prime Therapeutics Establishes Strategic Research Collaboration and License Agreement With Inhibrx for Novel GITR Antibodies
July 15, 2015Five Prime announces a strategic research collaboration with Inhibrx for Inhibrx's novel GITR antibody program, which will help expand Five Prime's immuno-oncology pipeline and potential for combination therapies.
More »
Celator(R) Pharmaceuticals Announces Start of Clinical Study of CPX-351 in Acute Myeloid Leukemia Patients at High Risk for Induction Mortality
July 14, 2015Celator announced that patients have been enrolled in an investigator-initiated Phase 2 clinical study evaluating CPX-351 Liposome Injection for newly diagnosed AML at high risk for induction treatment mortality.
More »
Xagenic Announces $15 Million Financing
July 9, 2015Xagenic announced that it has raised $15 Million. All Series B investors participated in this financing, including Domain, who is excited by the potential Xagenic holds to provide fast diagnostics for patients with infectious diseases.
More »